European Journal of Clinical Microbiology & Infectious Diseases最新文献

{"title":"Evolving patterns of healthcare-associated infections in NICU: a five-year retrospective analysis from a tertiary children's hospital in China.","authors":"Zhen Wang, Jiali Wang, Kouzhu Zhu, Yan-Jun Kang","doi":"10.1007/s10096-025-05103-x","DOIUrl":"https://doi.org/10.1007/s10096-025-05103-x","url":null,"abstract":"<p><strong>Background: </strong>Neonates in the NICU, particularly those born with very low birth weights, are at heightened risk for healthcare-associated infections (HAIs). Such infections can prolong hospitalization, increase medical costs, and potentially lead to adverse long-term outcomes. Recognizing evolving infection patterns and targeted prevention measures is essential to improving patient care.</p><p><strong>Methods: </strong>We retrospectively collected data on neonates admitted to the NICU of our hospital between January 2019 and December 2023. Information regarding HAI incidence, site of infection, device utilization, pathogen distribution, and antibiotic use was extracted and statistically analyzed. Comparisons regarding infection rates and clinical variables were performed using chi-square or Fisher's exact tests for categorical variables and Wilcoxon rank-sum tests for continuous variables.</p><p><strong>Results: </strong>Among 9786 neonates (70,509 patient-days), 86 HAI cases were identified (0.88%), corresponding to 1.22‰ infections per 1000 patient-days. Neonates with extremely low birth weight had significantly higher infection rates (13.04%) than other birth weight groups (p < 0.01). Bloodstream infections (35.87%) were the most common site, followed by respiratory and gastrointestinal infections (both 18.48%). Central line-associated bloodstream infection occurred at 0.75 infections per 1000 catheter-days, while ventilator-associated pneumonia decreased from 2.76‰ to 0.73‰ over the study period. Staphylococcus epidermidis was the predominant isolate among the pathogens identified. Neonates with HAIs had significantly longer antibiotic courses and higher rates of combination antibiotic therapy (p < 0.001).</p><p><strong>Conclusions: </strong>Although the overall incidence of NICU HAIs declined from 2019 to 2023, infection patterns continued to evolve, particularly regarding bloodstream infections. Prevention strategies must focus on high-risk neonates, rigorous device management, punctual surveillance of pathogen resistance, and prudent antibiotic use to further reduce infection morbidity and mortality in the NICU setting.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review of historical landmarks and pioneering technologies for the diagnosis of Hepatitis C Virus (HCV).","authors":"Kajal Sharma, Meesala Krishna Murthy","doi":"10.1007/s10096-025-05110-y","DOIUrl":"https://doi.org/10.1007/s10096-025-05110-y","url":null,"abstract":"<p><strong>Background: </strong>Since the progress of hepatitis C Virus (HCV) infection to chronic liver disease and finally cirrhosis and hepatocellular carcinoma, HCV infection has become a worldwide challenge to public health.</p><p><strong>Results: </strong>The progression from liver biopsy and antibody based test to the current time in the advancements in HCV diagnostic method is reviewed in this analysis with detailed discussion of enzyme immunoassay (EIAs), nucleic acid tests (NATs) and genotyping in enhancing accuracy of HCV detection. Next generation sequencing (NGS) and point of care testing (POCT) provided fast and economical diagnostic solutions. However, as promising diagnostic tools, Artificial Intelligence (AI) as well as Machine Learning (ML) can only be used in well-resourced environments, whereas Rapid Diagnostic Tests (RDTs) are advantageous for low and middle income countries.</p><p><strong>Conclusion: </strong>This review discusses some of the future challenges that face lowering of diagnostic costs in low resource settings and promoting early detection, some of which can be addressed by microfluidic platforms. Research in this area is far from over, and past and ongoing research has tremendous potential to access new technology for a myriad of purposes in the course of HCV control and global HCV elimination.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143677065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RE: 'Catheter replacement in catheter-associated urinary tract infection: current state of evidence' by Westgeest et al.","authors":"Jodie Langbeen, Frederik Van Hoecke, Veroniek Saegeman, Dana Van Kerkhoven, Hilde Jansens, Nicole Depont, Dirk Vogelaers","doi":"10.1007/s10096-025-05089-6","DOIUrl":"https://doi.org/10.1007/s10096-025-05089-6","url":null,"abstract":"","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and associated factors of macrolide-resistant mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.","authors":"Shuo Yang, Xinying Liu, Yaowei Han, Huizhe Wang, Yunzheng Mei, Haokai Wang, Na Zhang, Yingying Peng, Xinmin Li","doi":"10.1007/s10096-025-05101-z","DOIUrl":"https://doi.org/10.1007/s10096-025-05101-z","url":null,"abstract":"&lt;p&gt;&lt;p&gt;In recent years, the incidence of macrolide-resistant Mycoplasma pneumoniae (MRMP) pneumonia has markedly increased across East Asia, especially in China, Japan, and South Korea, presenting considerable challenges for clinical management. We systematically reviewed and conducted a meta-analysis on the resistance rate, clinical characteristics, and associated factors of MRMP, thereby establishing a foundation for early clinical identification and optimization of treatment strategies. In accordance with the PRISMA 2020 reporting guidelines, six databases including PubMed, Embase, Web of Science, CNKI, VIP, and Wanfang Data were systematically searched for relevant literature up to October 31, 2024. Studies explicitly reporting the clinical characteristics of both MRMP and macrolide-sensitive Mycoplasma pneumoniae (MSMP) pneumonia patients were included, with the population restricted to children. Pooled odds ratio (OR) and mean difference (MD), along with 95% confidence intervals, were calculated using inverse-variance weighting. A significance threshold was set at p &lt; 0.05, and meta-analysis was performed using software such as RevMan, Stata, and R Studio. A total of 65 studies encompassing 20,141 patients were included in this analysis. The meta-analysis revealed that MRMP showed high resistance in East Asia compared to lower resistance in other regions. The overall resistance rate was 61% (95% CI: 54%, 68%), exhibiting notable regional variation. Elevated resistance rates were noted in East Asian countries, specifically China, Japan, and South Korea, reported at 68% (95% CI: 63%, 73%), 61% (95% CI: 43%, 80%), and 63% (95% CI: 42%, 85%), respectively. MRMP resistance was significantly associated with prolonged fever duration (MD: 1.97, 95% CI: 1.10, 2.84), extended hospitalization (MD: 1.96, 95% CI: 1.39, 2.54), elevated log MP-DNA levels (MD: 2.79, 95% CI: 1.54, 4.04), increased proportions of severe (OR: 2.45, 95% CI: 1.75, 3.44) cases and refractory (OR: 3.25, 95% CI: 1.47, 7.17) cases, and the occurrence of complications, particularly intrapulmonary manifestations including pulmonary consolidations (OR: 1.43, 95% CI: 1.14, 1.78), pleural effusions (OR: 2.11, 95% CI: 1.28, 3.49), lobar lesions (OR: 2.03, 95% CI: 1.03, 4.00), mucus plugs (OR: 4.63, 95% CI: 1.66, 12.94), and necrotizing pneumonia (OR: 2.49, 95% CI: 1.19, 5.24), alongside extrapulmonary involvement (OR: 3.08, 95% CI: 2.49, 3.82). No significant differences were observed in peak body temperature (MD: 0.05, 95% CI: -0.11, 0.20) or inflammatory markers including white blood cell count (WBC, MD: 0.28, 95% CI: -0.38, 0.94), C-reactive protein (CRP, MD: 0.71, 95% CI: -2.16, 3.58), Procalcitonin (PCT, MD: -0.11, 95% CI: -0.27, 0.05) and lactate dehydrogenase (LDH, MD: 3.80, 95% CI: -22.92, 30.52). The high resistance rate may be associated with environmental pressure stemming from the widespread use of macrolide antibiotics and increased genetic mutations due to the extensive spre","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143662900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigational antibiotic cefepime/zidebactam as a therapeutic option for the treatment of an unyielding empyema in a paediatric patient caused by extensively drug-resistant Pseudomonas aeruginosa: a case report.","authors":"Vishnu Rao Polati, Santosh Gattu, Venkata Nagarjuna Maturu, P Swati Prakasham, Maryam Maqsood","doi":"10.1007/s10096-025-05106-8","DOIUrl":"https://doi.org/10.1007/s10096-025-05106-8","url":null,"abstract":"<p><strong>Objective: </strong>Treatment option for the infections caused by MBL-producing P. aeruginosa is severely limited. Cefepime/zidebactam (WCK 5222) is a novel β-lactam/ β-lactam-enhancer combination, currently in global Phase 3 clinical development. It is reported to show a broad-spectrum in vitro activity and translational efficacy in non-clinical PK/PD models against carbapenem-resistant Gram-negative bacteria including MBL-producing P. aeruginosa. We present a case of a 13-year-old girl, suffering from tuberculosis with a refractory lung empyema caused by NDM-producing, XDR P. aeruginosa who did not respond to several rounds of colistin or aztreonam plus ceftazidime/avibactam therapies albeit effective source control, over 4 months period.</p><p><strong>Methods: </strong>The infecting organism was found to be susceptible to cefepime/zidebactam. After obtaining informed consent and necessary approvals, the patient was treated under compassionate ground.</p><p><strong>Results: </strong>The patient was treated with adult dose regimen of cefepime/zidebactam (due to higher body weight) for 21 days that led to clinical and microbiological cure.</p><p><strong>Conclusion: </strong>This case highlights both severity of the antimicrobial resistance and hope offered by an under-trial novel antibiotic.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A novel comparative evaluation of multiplex PCR panels for gastrointestinal pathogen detection: Seegene Allplex™ vs. Luminex NxTAG^® in clinical stool samples.","authors":"Laura Seijas-Pereda, Ana Martín, Raquel Menchero, Carlos Rescalvo-Casas, Marcos Hernando-Gozalo, Juan Cuadros-González, Ramón Pérez-Tanoira","doi":"10.1007/s10096-025-05098-5","DOIUrl":"https://doi.org/10.1007/s10096-025-05098-5","url":null,"abstract":"<p><strong>Purpose: </strong>Accurate and rapid diagnosis of gastrointestinal infections is essential for effective patient management. This study compared the diagnostic performance of two multiplex PCR panels- the Seegene Allplex™ Gastrointestinal Panels (Seegene, Seoul, Korea) and the Luminex NxTAG^® Gastrointestinal Pathogen Panel (Luminex Corporation, Austin, Texas, a Diasorin Company)-in detecting gastrointestinal pathogens from clinical stool samples.</p><p><strong>Methods: </strong>A total of 196 stool samples, collected from patients at a Spanish hospital during 2023, were analyzed using both assays through prospective and retrospective approaches. The performance of each test was assessed based on Positive Percentage Agreement (PPA), Negative Percentage Agreement (NPA), and overall agreement. Discrepancies between methods were resolved with a third confirmatory technique when available.</p><p><strong>Results: </strong>Both assays demonstrated high overall concordance, with NPA values consistently above 95% and overall Kappa values exceeding 0.8 for most pathogens. The average PPA was greater than 89% for nearly all targets; however, lower agreement was observed for Cryptosporidium spp. (86.6%). Notably, discrepancies were primarily observed for certain pathogens, such as Salmonella spp. and Cryptosporidium spp., highlighting the diagnostic challenges associated with these targets.</p><p><strong>Conclusion: </strong>To our knowledge, this is the first study to compare the novel Luminex NxTAG^® panels from Diasorin with the Seegene Allplex™. Both multiplex assays provide rapid and reliable detection of gastrointestinal pathogens, making them valuable tools in clinical diagnostics. Future research should focus on improving detection accuracy for challenging pathogens and expanding target panels to further enhance patient management and reduce disease burden.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ceftazidime-avibactam use in hematology patients: single-center experience.","authors":"Aysun Halacoglu, Mustafa Koroglu, Mehmet Ozen","doi":"10.1007/s10096-025-05107-7","DOIUrl":"https://doi.org/10.1007/s10096-025-05107-7","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the efficacy of the cephalosporin/ beta lactamase inhibitor combination ceftazidime-avibactam in hematology patients with hematopoietic stem cell transplantation or receiving chemotherapy alone.</p><p><strong>Materials and methods: </strong>In this study, 80 patients who were followed up in the Stem Cell Transplant Center and Hematology Clinic of Istinye University Gaziosmanpaşa Medicalpark Hospital between June 2022 and May 2024 and who received ceftazidime-avibactam treatment for at least 3 days during their hospitalization were evaluated. Demographic characteristics, infectious processes, duration of hospitalization before culture, neutrophil levels and neutropenia duration at the time of treatment initiation, previous antibiotic exposure, Charlson's Comorbidity index, mechanical ventilation needs and mortality rates were recorded retrospectively.</p><p><strong>Results: </strong>Of the patients, 25 (31.25%) were female and 55 (68.75%) were male. The mean age was 50 years (18-86). Thirty-four (42.5%) patients received allogeneic hematopoietic stem cell transplantation and 17 (21.25%) patients received autologous hematopoietic stem cell transplantation. Only 29 (36.25%) patients received chemotherapy. When ceftazidime-avibactam treatment was initiated, 42 (52.5%) patients had a neutrophil count < 0.1 × 10⁹/L. Charlson's Comorbidity Index was ≥ 3 in 71 (88.75%) patients. Forty-six (57.5%) patients died in the first 28 days after the onset of infection. In multivariate analysis showed that mean age (HR 1.71, CI 1.07-3.05; p = 0.012), pneumonia and need for mechanical ventilation (HR 1.91, CI 1.83-1.98; p = 0.001), clinical improvement status in the first 14 days (HR 1.02, CI 0.97-1.08; p = 0.001) and duration of neutropenia (HR 2.67, CI 2.26-3.08; p = 0.019) were independent risk factors associated with 28-day mortality.</p><p><strong>Conclusion: </strong>Mortality due to resistant microorganisms is high in hematologic patients during stem cell transplantation and non-transplant period. Age, pneumonia and need for mechanical ventilation and duration of neutropenia are the most important mortality indicators in hematologic patients. Ceftazidime-avibactam is an effective treatment option in appropriate patients and the clinical response will be better if it can be started before the need for mechanical ventilation develops.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143647737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interpretation of pathogenicity and clinical features of multiple pathogens in pediatric lower respiratory tract infections by tNGS RPTM analysis.","authors":"Yujia Xiao, Dekyi, Xia Wang, Shuwen Feng, Yiyu Yang, Junwen Zheng, Dongchi Zhao","doi":"10.1007/s10096-025-05094-9","DOIUrl":"https://doi.org/10.1007/s10096-025-05094-9","url":null,"abstract":"<p><strong>Background: </strong>To characterize the epidemiology of pathogens in children with lower respiratory tract infections (LRTI) using targeted next-generation sequencing (tNGS), assess the correlation between reads per ten million (RPTM) of co-detected pathogens, identify common co-detection patterns, and explore their clinical significance.</p><p><strong>Methods: </strong>Children aged 29 days to 14 years hospitalized for LRTI at the Department of Pediatrics, Zhongnan Hospital of Wuhan University, from April 2023 to August 2024 were included. Bronchoalveolar lavage fluid (BALF) or nasopharyngeal swab (NS) samples were tested for pathogens using tNGS, and clinical data were collected. The data and RPTM were statistically analyzed based on lung X-ray and CT scan results, classifying cases as pneumonia or lung consolidation/pulmonary atelectasis (LC/PA).</p><p><strong>Results: </strong>Among 1118 children, the highest pathogen detection rate was Mycoplasma pneumoniae (MP) at 60.20%, followed by Haemophilus influenzae (HI) at 42.40% and Streptococcus pneumoniae (SP) at 35.42%. In children under 4 years old, common pathogens were HI, Rhinovirus (RhV), and Respiratory syncytial virus (RSV). For those over 4 years old, MP and HI were predominant. In common pneumonia cases, MP, HI, and RhV were frequent, with MP being the primary pathogen in LC/PA. 80.70% of respiratory samples detected two or more pathogens, and viruses were more frequently detected in NS than in BALF. Correlation analysis showed that MP RPTM was negatively correlated with other co-detected pathogens' RPTM, SP was negatively correlated with RSV but positively correlated with Influenza virus (flu virus), HI was positively correlated with Adenovirus (ADV) and flu virus, RhV was negatively correlated with flu virus. Clinical characteristics of co-detected pathogens showed no significant differences in acute LRTI symptoms among different combinations.</p><p><strong>Conclusion: </strong>Co-detection of pathogens in children's LRTI using tNGS was common, with MP and bacterial infections being predominant. There were synergistic and competitive relationships between the RPTM of co-detected pathogens.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to: Outpatient parenteral antibiotic therapy in non-cystic fibrosis lung transplant recipients: characteristics, efficacy and safety.","authors":"Bart Forier, Veronique Schaevers, Isabel Spriet, Charlotte Quintens, Stefanie Desmet, Saskia Bos, Pascal Van Bleyenbergh, Natalie Lorent, Laurens De Sadeleer, Laurent Godinas, Lieven J Dupont, Robin Vos","doi":"10.1007/s10096-025-05092-x","DOIUrl":"https://doi.org/10.1007/s10096-025-05092-x","url":null,"abstract":"","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiological, clinical and microbiological aspects of infective endocarditis in Türkiye.","authors":"Elif M Saricaoglu, Seniha Basaran, Derya Seyman, Merve Arslan, Serpil Ozkan-Ozturk, Yasemin Tezer-Tekce, Yesim Uygun-Kizmaz, Nuran Sari, Denef Berzeg-Deniz, Alpay Azap, Serap Simsek-Yavuz, Ozlem Kurt-Azap","doi":"10.1007/s10096-025-05095-8","DOIUrl":"https://doi.org/10.1007/s10096-025-05095-8","url":null,"abstract":"<p><strong>Purpose: </strong>Infective endocarditis (IE) is a evolving disease with a shifting epidemiology and disease burden over time. This study aimed to compare the epidemiological and clinical aspects of IE over three time periods across eleven years.</p><p><strong>Methods: </strong>This was a retrospective cohort, multicenter study conducted in Türkiye, comparing three periods: 2013-2016, 2017-2020, and 2021-2023. Epidemiological and microbiological characteristics, as well as patient outcomes, were analyzed and compared across these periods.</p><p><strong>Results: </strong>A total of 1,044 patients diagnosed with IE were included. The median (Q1-Q3) age was 57 (44-68) years, with an increasing pattern (p < 0.001). Throughout the study period, the prevalence of intracardiac devices increased, whereas the prevalence of degenerative and congenital heart diseases declined. Among all patients, the most frequently identified pathogens were staphylococci (36.4%), followed by streptococci (14.0%) and enterococci (11.9%). Throughout the three periods, there was a significant increase in staphylococci, with S. aureus emerging as the predominant pathogen in all type IE. The in-hospital mortality rate among all patients was 22.5%. Independent risk factors for in-hospital mortality included ≥ 65 age(OR = 1.9), chronic kidney disease (OR = 1.9), nosocomial acquisition (OR = 2.1), Candida spp. infection (OR = 2.9), prosthetic valve IE (OR = 1.9), vegetation size > 15 mm (OR = 1.6), and central nervous system emboli (OR = 2).</p><p><strong>Conclusion: </strong>The epidemiology of IE is undergoing significant changes, leading to shifts in microbiological profiles and clinical presentations. Effective management of IE should be guided by established clinical guidelines while integrating up-to-date epidemiological data to ensure comprehensive and evidence-based patient care.</p>","PeriodicalId":11782,"journal":{"name":"European Journal of Clinical Microbiology & Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143630350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}